The influence of inadequate starting empirical antimicrobial therapy of septic pneumonia on outcomes at patients with angiogenic sepsis Source: Eur Respir J 2004; 24: Suppl. 48, 549s Year: 2004
Effects of nebulised iloprost on pulmonary function and oxygenation in patients with severe pulmonary hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 370s Year: 2002
Risk assessment and prognosis in patients with pulmonary arterial hypertension receiving intravenous treprostinil Source: International Congress 2019 – Endpoints and risk assessment of pulmonary arterial hypertension Year: 2019
Sildenafil for treatment of associated pulmonary hypertension in patients with severe COVID-19 pneumonia. Source: Virtual Congress 2021 – Pulmonary hypertension in the COVID-19 pandemic and beyond Year: 2021
Changes in the vascular platelet phase of hemostasis in patients with septic and traumatic shock, presenting ARDS Source: Eur Respir J 2004; 24: Suppl. 48, 264s Year: 2004
Oral sildenafil is a potent pulmonary vasodilator and improves gas exchange in patients with COPD with pulmonary hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 426s Year: 2006
Endothelial dysfunction and prognostic significance of endothelin-1 in patients with severe pneumonia and pulmonary sepsis Source: International Congress 2015 – Immunodepression and severe pneumonia Year: 2015
Experience with pulmonary selective vasodilator treatment in COPD with severe pulmonary hypertension Source: Annual Congress 2011 - Pulmonary hypertension in hypoxic lung disease Year: 2011
CPAP therapy in the ambulance vehicle in patients with acute cardiogenic pulmonary oedema Source: Eur Respir J 2007; 30: Suppl. 51, 264s Year: 2007
CPAP treatment of acute cardiogenic pulmonary edema (ACPE) in very elderly patients Source: Eur Respir J 2005; 26: Suppl. 49, 443s Year: 2005
Effect of riociguat on pulmonary arterial compliance (PAC) in patients with CTEPH in the CHEST-1 study Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots Year: 2015
Effects of pulmonary rehabilitation on systemic and pulmonary inflammation in COPD patients Source: Annual Congress 2010 - Exercise in COPD Year: 2010
Pulmonary hypertension and endothelial dysfunction in patients with COPD Source: Eur Respir J 2007; 30: Suppl. 51, 605s Year: 2007
Consistency of the acute hemodynamic response to inhaled iloprost in pulmonary hypertension patients treated long-term with iloprost aerosol Source: Eur Respir J 2001; 18: Suppl. 33, 323s Year: 2001
Systemic endothelial dysfunction in COPD patients – study on 60 cases Source: Eur Respir J 2004; 24: Suppl. 48, 61s Year: 2004
Hypoxaemia and endothelial dysfunctional in patients with COPD Source: Annual Congress 2009 - Respiratory mechanics, tissue and cell dysfunction in pulmonary disease Year: 2009
Systemic inflammation and endothelial dysfunction in patient with COPD Source: Eur Respir J 2007; 30: Suppl. 51, 143s Year: 2007
Usefulness of a selective neutrophil elastase inhibitor and a recombinant human soluble thrombomodulin in patients with ARDS and DIC Source: Annual Congress 2013 –Acute respiratory failure, ARDS and severe COPD exacerbations Year: 2013
Systemic inflammation and pulmonary hypertension in patients with COPD Source: Eur Respir J 2007; 30: Suppl. 51, 142s Year: 2007
Intravenous iloprost as "rescue therapy" in patients with severe primary pulmonary hypertension deteriorating while on chronic aerosolized iloprost therapy Source: Eur Respir J 2004; 24: Suppl. 48, 705s Year: 2004